Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis.
Cladribine tablets
Disease-modifying therapy
Drug safety
Immune reconstitution therapy
Multiple sclerosis
Journal
Neurology and therapy
ISSN: 2193-8253
Titre abrégé: Neurol Ther
Pays: New Zealand
ID NLM: 101637818
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
21
03
2023
accepted:
11
05
2023
medline:
29
6
2023
pubmed:
29
6
2023
entrez:
29
6
2023
Statut:
ppublish
Résumé
Cladribine tablets (CladT) is a highly active oral disease-modifying therapy (DMT) for the management of relapsing multiple sclerosis (RMS). CladT acts as an immune reconstitution therapy, in that two short courses of treatment 1 year apart have been shown to suppress disease activity for a prolonged period in most patients, without need for continued DMT. Each course of CladT induces a profound reduction in B lymphocytes that recovers over months, and serious lymphopenia (Grade 3-4) is uncommon. Smaller reductions in levels of T lymphocytes occur slightly later: on average, these remain within the normal range and repopulate progressively. A larger effect occurs on CD8 vs. CD4 cells. Reactivation of latent or opportunistic infections (e.g. varicella zoster, tuberculosis) is mostly associated with very low lymphocyte counts (< 200/mm
Identifiants
pubmed: 37382841
doi: 10.1007/s40120-023-00496-3
pii: 10.1007/s40120-023-00496-3
pmc: PMC10444734
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1457-1476Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2023. The Author(s).
Références
J Neurol. 2020 Nov;267(11):3343-3353
pubmed: 32583052
Mult Scler Relat Disord. 2020 Nov;46:102572
pubmed: 33296971
Ther Adv Neurol Disord. 2021 Apr 23;14:1756286420982134
pubmed: 34035833
Mult Scler. 2023 Mar;29(3):461-465
pubmed: 36278327
Lancet. 2012 Nov 24;380(9856):1829-39
pubmed: 23122650
Neurol Ther. 2019 Jun;8(1):13-23
pubmed: 30875021
Neurol Neuroimmunol Neuroinflamm. 2015 Oct 01;2(6):e158
pubmed: 26468472
Wien Med Wochenschr. 2022 Nov;172(15-16):365-372
pubmed: 35451662
Mult Scler Relat Disord. 2021 Jul;52:102945
pubmed: 33901969
Curr Neuropharmacol. 2022;20(10):1811-1815
pubmed: 34923946
Curr Med Res Opin. 2022 Jul;38(7):1167-1176
pubmed: 35357268
Mult Scler Int. 2021 Feb 15;2021:6667006
pubmed: 33628508
Lancet. 2012 Nov 24;380(9856):1819-28
pubmed: 23122652
Mult Scler Relat Disord. 2022 Nov;67:104184
pubmed: 36174258
Ther Adv Neurol Disord. 2021 Apr 22;14:17562864211012835
pubmed: 34035836
Mult Scler. 2022 Nov;28(13):2142-2145
pubmed: 36169305
J Neurol. 2022 Jul;269(7):3937-3958
pubmed: 35399125
J Neurol. 2021 Aug;268(8):2697-2699
pubmed: 33216223
Front Immunol. 2018 Jul 09;9:1560
pubmed: 30050529
Mult Scler J Exp Transl Clin. 2021 Jul 13;7(3):20552173211024298
pubmed: 34345436
J Neurol Neurosurg Psychiatry. 2022 Sep;93(9):986-994
pubmed: 35688629
Biomedicines. 2021 Oct 31;9(11):
pubmed: 34829815
Neurol Ther. 2020 Jun;9(1):55-66
pubmed: 32297127
Neurol Ther. 2020 Dec;9(2):265-280
pubmed: 32564333
Mult Scler Relat Disord. 2022 Jan;57:103385
pubmed: 35158476
Brain. 2022 Jun 3;145(5):1711-1725
pubmed: 35661859
Front Neurol. 2021 Jul 01;12:697974
pubmed: 34276545
EBioMedicine. 2021 Oct;72:103581
pubmed: 34563483
Autoimmun Rev. 2020 Apr;19(4):102492
pubmed: 32062028
N Engl J Med. 2010 Feb 4;362(5):416-26
pubmed: 20089960
Eur J Neurol. 2022 Jan;29(1):257-266
pubmed: 34558755
Drug Saf. 2020 Jul;43(7):635-643
pubmed: 32447743
Neurol Ther. 2020 Dec;9(2):599-604
pubmed: 32712904
Br J Clin Pharmacol. 2021 Dec;87(12):4769-4779
pubmed: 33998034
Mult Scler. 2019 Aug;25(9):1206-1208
pubmed: 31368417
J Neuroimmunol. 2021 Dec 15;361:577746
pubmed: 34655991
Curr Med Res Opin. 2018 Aug;34(8):1361-1371
pubmed: 29149804
Neurol Ther. 2019 Dec;8(2):231-240
pubmed: 31696392
JAMA Netw Open. 2022 Jan 4;5(1):e2144750
pubmed: 35072719
Mult Scler Relat Disord. 2022 Jan;57:103343
pubmed: 35158452
Neurol Neuroimmunol Neuroinflamm. 2022 Aug 29;9(6):
pubmed: 36038263
Neurol Ther. 2019 Dec;8(2):241-250
pubmed: 31677060
Mult Scler. 2018 Oct;24(12):1594-1604
pubmed: 28870107
Mult Scler Relat Disord. 2022 May;61:103755
pubmed: 35483129
Ther Adv Neurol Disord. 2021 Jul 22;14:17562864211019598
pubmed: 34671422
Neurol Sci. 2022 Sep;43(9):5479-5500
pubmed: 35713731
Mult Scler. 2022 Apr;28(5):842-846
pubmed: 34882037
Neurol Ther. 2021 Dec;10(2):539-555
pubmed: 34138444
J Neurol. 2019 Jun;266(6):1405-1411
pubmed: 30863891
Neurol Ther. 2022 Sep;11(3):1193-1208
pubmed: 35653061
Ther Adv Neurol Disord. 2020 Jun 24;13:1756286420935019
pubmed: 32636933
Mult Scler Relat Disord. 2022 Dec;68:104156
pubmed: 36137347
Mult Scler Relat Disord. 2019 Apr;29:168-174
pubmed: 30885375
Ther Adv Neurol Disord. 2021 Dec 07;14:17562864211058298
pubmed: 34899987
Mult Scler. 2022 Feb;28(2):257-268
pubmed: 33975489
Mult Scler. 2022 Jul;28(8):1219-1228
pubmed: 34634968
Case Rep Womens Health. 2019 Nov 20;25:e00162
pubmed: 31867224
Ther Adv Neurol Disord. 2019 Jun 18;12:1756286419854986
pubmed: 31244898
Ann Neurol. 2021 Apr;89(4):780-789
pubmed: 33480077
Neurol Ther. 2023 Apr;12(2):351-369
pubmed: 36564664
Front Immunol. 2021 Dec 24;12:763433
pubmed: 35003076
Pract Neurol. 2019 Apr;19(2):106-114
pubmed: 30612100
Ther Adv Neurol Disord. 2020 Jun 10;13:1756286420922685
pubmed: 32587633
Mult Scler Relat Disord. 2021 Nov;56:103225
pubmed: 34479111
Ther Adv Neurol Disord. 2019 Mar 28;12:1756286419836913
pubmed: 30944586
Mult Scler Relat Disord. 2022 Jul;63:103887
pubmed: 35636269
Clin Pharmacokinet. 1997 Feb;32(2):120-31
pubmed: 9068927
Neurol Sci. 2021 Nov;42(11):4591-4597
pubmed: 33660157
Mult Scler Relat Disord. 2022 Feb;58:103490
pubmed: 35007823
Neurology. 2016 Nov 8;87(19):1985-1992
pubmed: 27733571
Mult Scler. 2022 Nov;28(13):2146
pubmed: 36169282
Ther Adv Neurol Disord. 2019 Mar 29;12:1756286419837809
pubmed: 30956686